

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: McDONALD et al.

Serial No. 09/360,242

Filed: July 22, 1999

For: *METHODS AND COMPOSITIONS FOR
TREATING SECONDARY TISSUE
DAMAGE AND OTHER
INFLAMMATORY CONDITIONS AND
DISORDERS*

Art Unit: 1646

Examiner: Landsman, R.



I hereby certify that this paper is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Assistant Commissioner for Patents, Washington, D.C. 20231, on this date.

12/13/99
Date


Kathy Holloway

DECLARATION

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

I, STEPHANIE SEIDMAN, declare as follows:

1) I am applicant's attorney responsible for prosecuting the above-captioned application.


2) The amendments to the sequence listing and in the specification at page 6, line 21, inserting SEQ ID NO. 93;
at page 58, line 12, inserting SEQ ID NO. 92;
at page 65, line 17, inserting SEQ ID NO. 90;
at page 65, line 19, inserting SEQ ID NO. 89;
at page 65, line 20, inserting SEQ ID NO. 91;
at page 65, line 21, inserting SEQ ID NO. 92; and

inclusion of SEQ ID NOs. 89-93 in the Sequence Listing setting forth the sequences of various chemokines are identical to the respective sequences set forth in references that are incorporated by reference into the specification. In particular, SEQ ID NOS. 89-92 are identical to the sequences set forth in Clark-Lewis *et al.* (1995) *J Leukoc Biol* 57, 703-11, cited at page 2, line 20 of the specification as originally filed, and SEQ ID NO. 93 is described in Shirozu *et al.*,

USSN 09/360,242
McDONALD *et al.*
DECLARATION

Genomics, 28: 495-500. 1995, cited at page 6, line 24 of the specification as originally filed. The specification as originally filed specifically incorporates all citations by reference (see page 30, lines 1-8).

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent resulting therefrom.



STEPHANIE SEIDMAN
Registration No. 33,779

Date: December 13, 1999
25020-601B